Skip to content

Evaluating a Cytomegalovirus (CMV) Vaccine in Healthy female Participants 18 to 40 Years of Age

Healthy Volunteers | CMV | Cytomegalovirus | Vaccine

This research study is testing a study vaccine (mRNA-1647) that is being developed for preventing cytomegalovirus (CMV) infection. CMV is a common virus that can spread easily through an infected person’s saliva, blood, urine and breast milk. It is unusual for a CMV infection in a healthy person to cause illness and when it does symptoms are relatively mild.

However, if a pregnant woman has a CMV infection, it may be passed to her unborn child. Children born with CMV can suffer long-term disability due to birth defects, including hearing loss or even death in very severe cases. CMV is the leading cause of birth defects around the world.

There is currently no approved vaccine to prevent CMV infection.

null

Participation Requirements

  • Sex:

    Female

  • Eligible Ages:

    18 to 40

Participation Criteria

Inclusion Criteria:
- Healthy females aged 18 - 40
- If more than 20 years old, must have regular contact with small children
- Not currently pregnant or planning on becoming pregnant within the next 9 months
Exclusion Criteria:
- Immunosuppressed individuals
- Skin conditions or tattoos over upper arm that could affect ability to see skin reaction to vaccine injection
- Severe allergy to other vaccines
- Severe bleeding condition
- Other unstable medical conditions
- If receiving any other vaccines, they will need to be spaced apart from the study vaccine
- Receiving antiviral medications that are active against CMV infection
- Received or donated immunoglobulins or blood products recently
- Currently participating in another study with active treatment

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Research Coordinator

[email protected]
780-407-6945
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00112395